Noa Krugliak Cleveland, MD, is a board-certified physician who specializes in gastroenterology. Dr. Krugliak Cleveland has advanced training in inflammatory bowel disease (IBD) and sees patient with ulcerative colitis and Crohn’s disease. She is interested in the use of novel therapies to treat IBD and use of new technologies for the detection and management of cancer and inflammation in IBD including bedside intestinal ultrasound.
Along with her clinical expertise, Dr. Krugliak Cleveland is also a physician-scientist, whose research focuses on disease outcomes and prevention of IBD complications. She investigates the application of new technology for the detection and prevention of progression of IBD. Her work has been published in several peer-reviewed journals, including Gastroenterology, The American Journal of Gastroenterology, Inflammatory Bowel Diseases, Clinical Gastroenterology and Hepatology, Digestive Diseases and Sciences and more.
International Magnetic Resonance Imaging Consensus for use in Luminal Crohn's Disease Trials and Clinical Practice.
International Magnetic Resonance Imaging Consensus for use in Luminal Crohn's Disease Trials and Clinical Practice. Clin Gastroenterol Hepatol. 2025 Aug 27.
PMID: 40882718
Point-of-Care Ultrasound in Gastroenterology and Hepatology.
Point-of-Care Ultrasound in Gastroenterology and Hepatology. Clin Gastroenterol Hepatol. 2025 Jul; 23(8):1277-1290.
PMID: 39793722
Dose escalation of biologics in biologic-naive patients with Crohn's disease: Outcomes from the ODESSA-CD study.
Dose escalation of biologics in biologic-naive patients with Crohn's disease: Outcomes from the ODESSA-CD study. J Manag Care Spec Pharm. 2024 Nov; 30(11):1276-1287.
PMID: 39471266
Ultrasonographic Transmural Healing in Crohn's Disease.
Ultrasonographic Transmural Healing in Crohn's Disease. Am J Gastroenterol. 2023 06 01; 118(6):961-969.
PMID: 36988302
The Arrival of Intestinal Ultrasound for Inflammatory Bowel Disease Care in the United States.
The Arrival of Intestinal Ultrasound for Inflammatory Bowel Disease Care in the United States. Gastroenterol Hepatol (N Y). 2023 Mar; 19(3):147-154.
PMID: 37706105
Hypertensive Emergency After Initiating Ozanimod: A Case Report.
Hypertensive Emergency After Initiating Ozanimod: A Case Report. Inflamm Bowel Dis. 2022 08 01; 28(8):e114-e115.
PMID: 35212384
Ozanimod in the Treatment of Ulcerative Colitis: Initial Real-World Data From a Large Tertiary Center.
Ozanimod in the Treatment of Ulcerative Colitis: Initial Real-World Data From a Large Tertiary Center. Clin Gastroenterol Hepatol. 2023 08; 21(9):2407-2409.e2.
PMID: 35381385
CANCER PREVENTION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE.
CANCER PREVENTION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE. Pract Gastroenterol. 2021 Aug; 45(8):12-28.
PMID: 34707325
Use of Tofacitinib for the Treatment of Arthritis Associated With Ulcerative Colitis.
Use of Tofacitinib for the Treatment of Arthritis Associated With Ulcerative Colitis. ACG Case Rep J. 2019 Sep; 6(9):e00226.
PMID: 31750389
The Role of Biosimilars in Inflammatory Bowel Disease.
The Role of Biosimilars in Inflammatory Bowel Disease. Gastroenterol Hepatol (N Y). 2016 Dec; 12(12):741-751.
PMID: 28035201